PHARMACOECONOMIC ANALYSIS OF THERAPY REGIMENS FOR AGGRESSIVE 79 LYMPHOMA AND HODGKIN LYMPHOMA

The registration of new drugs significantly expands the possibilities hematologists and oncologists in treatment tumors lymphoid tissue. cost monoclonal antibodies, inhibitors various signaling pathways immune checkpoints disproportionately exceeds direct "classical" programs combined cytostatic therapy. regimens included National Clinical Guidelines remain basis first-line therapy, are with agents, standards comparison efficacy for agents. Regional population registries can be a source useful information on quantities basic first- subsequent-line agents needed size financial costs providing therapy to patients hemoblastosis.